C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 231/12 (2006.01) A61K 31/415 (2006.01) A61K 31/4155 (2006.01) A61K 31/416 (2006.01) A61P 9/00 (2006.01) A61P 11/00 (2006.01) C07D 231/18 (2006.01) C07D 231/54 (2006.01) C07D 231/56 (2006.01) C07D 401/04 (2006.01) C07D 405/04 (2006.01) C07D 409/04 (2006.01)
Patent
CA 2744124
Pyrazole derivatives of Formula la and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
Dérivés de pyrazole de Formule Ia et compositions pharmaceutiques les incluant qui modulent l'activité du récepteur PGI2. Les composés selon la présente invention et les compositions pharmaceutiques les incluant sont destinés à des méthodes pouvant être employées dans le traitement des pathologies suivantes : hypertension artérielle pulmonaire (HTAP) et troubles apparentés; agrégation plaquettaire; coronaropathie; infarctus du myocarde; accident ischémique transitoire; angine de poitrine; accident vasculaire cérébral; lésions d'ischémie-reperfusion; resténose; fibrillation auriculaire; formation d'un caillot sanguin au cours d'une chirurgie d'angioplastie ou de pontage coronarien chez un individu le nécessitant ou chez un individu souffrant de fibrillation auriculaire; athérosclérose; athérothrombose; asthme ou l'un de ses symptômes; troubles apparentés au diabète tels que neuropathie diabétique périphérique, néphropathie diabétique ou rétinopathie diabétique; glaucome ou autre pathologie oculaire impliquant une pression intra-oculaire anormale; hypertension; inflammation; psoriasis; rhumatisme psoriasique; polyarthrite rhumatoïde; maladie de Crohn; rejet de greffon; sclérose en plaques; lupus érythémateux disséminé (LED); rectocolite hémorragique; lésions d'ischémie-reperfusion; resténose; athérosclérose; acné; diabète de type 1; diabète de type 2; sepsie; et bronchopneumopathie chronique obstructive (BPCO).
Ibarra Jason B.
Shin Young-Jun
Tran Thuy-Anh
Ullman Brett
Zeng Xi
Arena Pharmaceuticals Inc.
Smart & Biggar
LandOfFree
Pyrazolyl substituted carbonic acid derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolyl substituted carbonic acid derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolyl substituted carbonic acid derivatives as... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1939573